<DOC>
	<DOCNO>NCT02009137</DOCNO>
	<brief_summary>Expected Total Number Subjects - Level significance , alfa 0.05 - Power 0.80 - Mean difference two treatment assume 35 - Standard Deviation assume 35 . - Follow-up loss assume 20 % - N=34 ( group:17 )</brief_summary>
	<brief_title>Efficacy Safety Study EVERA Augment Small Breast</brief_title>
	<detailed_description>Study design - single center , randomize , unblind clinical study Medical device - Investigational Medical Device : EVERA - Comparator : ESTES Process - For eligible subject , investigator apply Standard Deviation Comparator breast - The Investigational Medical Device determine randomization . - Subjects apply 12 week . - Subjects receive Patient Compliance Diary - Subjects visit hospital measure breast volume VIVID 9i every 2 week 16weeks</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<criteria>Female age 24 40 BMI 20 Subjects want augment breast Subjects understand study content sign informed consent Subjects follow study procedure Pregnant Lactating subject</criteria>
	<gender>Female</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>small breast</keyword>
	<keyword>augmentation</keyword>
	<keyword>breast volume</keyword>
	<keyword>External Soft Tissue Expansion System ( ESTES )</keyword>
</DOC>